Circulating GLAST⁺ EVs are increased in amyotrophic lateral sclerosis

Area of Science:

• Neuroscience
• Biochemistry
• Biomarker Discovery

Background:

• Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by motor neuron loss.
• Current diagnostic methods for ALS lack specific biomarkers, necessitating research into novel indicators.
• Extracellular vesicles (EVs) are increasingly recognized as valuable biomarkers due to their ability to reflect the central nervous system's pathological state.

Purpose of the Study:

• To investigate the potential of GLAST-positive extracellular vesicles (GLAST+ EVs) as biomarkers for amyotrophic lateral sclerosis (ALS).
• To explore the role of glutamate excitotoxicity, mediated by the GLAST transporter, in ALS pathogenesis.

Main Methods:

• A validated, rapid method was employed to quantify GLAST+ EVs in the plasma of ALS patients and age-matched healthy controls.
• Plasma samples were analyzed to detect and measure the concentration of EVs expressing the GLAST transporter.

Main Results:

• A significant increase in the levels of GLAST+ EVs was observed in the plasma of ALS patients compared to healthy controls.
• This finding suggests a correlation between elevated GLAST+ EVs and the presence of ALS.

Conclusions:

• GLAST+ EVs represent a promising, non-invasive biomarker candidate for ALS diagnosis and disease progression monitoring.
• Further research into GLAST+ EVs could unveil new therapeutic strategies targeting glutamate excitotoxicity in ALS.